| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, et Service d'Hématologie de l'Institut Gustave Roussy, Villejuif (Seine), France
The theoretical principle of treatment of acute leukemia by adoptive immunotherapy is to permit allogenic, immunologically competent cells to act against the host's leukemic cells and the basic leukemogenic factors present in the host. Such an effect may be obtained by a graft of allogenic hematopoietic cells following total-body irradiation. If the patient is able to survive the secondary syndrome that is induced by the homograft, an eradication of the leukemia may well be obtained. It has been demonstrated that this mode of therapy is effective in the treatment of spontaneous, transplanted, and viral leukemias in mice. Clinical trials of adoptive immunotherapy of acute leukemia in man are described. The results show that it is possible to obtain a sustained graft of hematopoietic cells and that such a graft has a distinct value as an anti-leukemic agent.
1 This study was carried out with the aid of CA 05703-04 RAD, NIH, Bethesda, Maryland.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |